Affinivax (Series B)

Funding Details
Awarder
Inbox
Date Award
April 23, 2020
Vertical
Biotechnology
Funding URL
View Funding Page
Funding Amount:
$120,000,000

Company Info
Traction
The lead pneumococcal vaccine includes 24 serotypes and is currently in Phase 2 clinical trials.
Organizations Involved
Astellas Pharma
Company Description
Affinivax is a biopharmaceutical company developing vaccines that target infectious diseases.
Market
Vaccines and Immunotherapies
Location
Cambridge, MA, USA
Coinvestors
Bain Capital Life Sciences, Viking Global Investors, Ziff Capital Partners, Bill & Melinda Gates Foundation

Links